Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Viking Therapeutics Inc (NASDAQ: VKTX) closed the day trading at $36.46 down -1.94% from the previous closing price of $37.18. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 1.87 million shares were traded. VKTX stock price reached its highest trading level at $37.09 during the session, while it also had its lowest trading level at $36.13.
Ratios:
For a better understanding of VKTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.34 and its Current Ratio is at 28.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 29, 2025, initiated with a Buy rating and assigned the stock a target price of $106.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $104.
On April 08, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $30.Goldman initiated its Neutral rating on April 08, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 28 ’25 when Mancini Marianna sold 6,185 shares for $35.00 per share. The transaction valued at 216,492 led to the insider holds 382,467 shares of the business.
Rowland Charles A Jr sold 60,000 shares of VKTX for $2,134,278 on Oct 27 ’25. The Director now owns 30,000 shares after completing the transaction at $35.57 per share. On Oct 28 ’25, another insider, Lian Brian, who serves as the President & CEO of the company, sold 38,989 shares for $35.01 each. As a result, the insider received 1,364,923 and left with 2,419,109 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 4121305088 and an Enterprise Value of 3407490048.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.69, which has changed by -0.076043725 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $43.55, while it has fallen to a 52-week low of $18.92. The 50-Day Moving Average of the stock is 0.68%, while the 200-Day Moving Average is calculated to be 20.02%.
Shares Statistics:
Over the past 3-months, VKTX traded about 3.83M shares per day on average, while over the past 10 days, VKTX traded about 2118940 shares per day. A total of 112.45M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 2.83% of the company’s shares, while institutions hold 65.27% stake in the company. Shares short for VKTX as of 1765756800 were 24029319 with a Short Ratio of 6.27, compared to 1763078400 on 24785654. Therefore, it implies a Short% of Shares Outstanding of 24029319 and a Short% of Float of 25.480000000000004.
Earnings Estimates
The market rating of Viking Therapeutics Inc (VKTX) is currently shaped by the ongoing analysis conducted by 14.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.76 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$2.07 and -$2.87 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$3.72, with 13.0 analysts recommending between -$3.13 and -$4.94.
